MAIA Biotechnology, Inc.

For the period ended Dec 31, 2024. Filed Mar 21, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 21, 2025

MAIA$1.09+2.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	December 31,2024	December 31,2023
ASSETS
Current assets:
Cash	$9,601,298	$7,150,695
Prepaid expenses and other current assets	473,834	268,677
Australia research and development incentives receivable	77,347	144,680
Total current assets	10,152,479	7,564,052
Other assets	2,800	2,800
Total assets	$10,155,279	$7,566,852
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$1,512,436	$1,638,546
Accrued expenses	2,317,602	3,298,607
Total current liabilities	3,830,038	4,937,153
Long term liabilities:
Warrant liability	2,690,605	2,152,188
Total liabilities	6,520,643	7,089,341
Commitments and contingencies (Note 7)
Stockholders' equity (deficit)
Preferred stock, $0.0001 par value, 30,000,000 shares authorized at December 31, 2024 and December 31, 2023, 0 shares issued and outstanding	—	—
Common stock, $0.0001 par value, 70,000,000 shares authorized at December 31, 2024 and December 31, 2023, 26,157,788 and 16,986,254 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively	2,616	1,699
Additional paid-in capital	90,897,468	64,472,249
Accumulated deficit	(87,234,833)	(63,980,177)
Accumulated other comprehensive loss	(30,615)	(16,260)
Total stockholders' equity	3,634,636	477,511
Total liabilities and stockholders' equity	$10,155,279	$7,566,852

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.